Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

Michele Stanislaw Milella(University of Verona), Michael Andreeff(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Investigation
September 15, 2001
10.1172/jci200112807
Cited by 24

Related Papers

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
|Blood|2001|570
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
|Blood|2001|516
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
|Nature Communications|2020|383